Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Eide

Showing results (21-30 of 83) with videos related to

Pageof 9
Sort By:
Cancer Research|July 18, 2019
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein DegradationGeorge M Burslem, Anna Reister Schultz, Daniel P Bondeson, et al.
Science Signaling|July 15, 2025
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminibSerena Muratcioglu, Christopher A Eide, Chien-Lun Hung, et al.
Blood|June 15, 2006
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinationsHeather A Bradeen, Christopher A Eide, Thomas O'Hare, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2015
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitorsMonika A Davare, Nadeem A Vellore, Jacob P Wagner, et al.
JCO Precision Oncology|January 21, 2026
DDX41-Mutated AML: A Case Report and PerspectivesWilliam M Yashar, Christopher A Eide, Stephen E Kurtz, et al.
Leukemia|May 6, 2020
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemiaSunil K Joshi, Jamie M Keck, Christopher A Eide, et al.
British Journal of Haematology|October 20, 2022
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemiaEvan J Barnes, Christopher A Eide, Andy Kaempf, et al.
Cancer Cell|July 9, 2010
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-AblMark A Gregory, Tzu L Phang, Paolo Neviani, et al.
Blood Advances|January 25, 2022
Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemiaStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2013
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteinsMonika A Davare, Anna Saborowski, Christopher A Eide, et al.
Pageof 9

Showing results (21-30 of 83) with videos related to

Sort By:
Pageof 9
Cancer Research|July 18, 2019
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein DegradationGeorge M Burslem, Anna Reister Schultz, Daniel P Bondeson, et al.
Science Signaling|July 15, 2025
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminibSerena Muratcioglu, Christopher A Eide, Chien-Lun Hung, et al.
Blood|June 15, 2006
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinationsHeather A Bradeen, Christopher A Eide, Thomas O'Hare, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2015
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitorsMonika A Davare, Nadeem A Vellore, Jacob P Wagner, et al.
JCO Precision Oncology|January 21, 2026
DDX41-Mutated AML: A Case Report and PerspectivesWilliam M Yashar, Christopher A Eide, Stephen E Kurtz, et al.
Leukemia|May 6, 2020
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemiaSunil K Joshi, Jamie M Keck, Christopher A Eide, et al.
British Journal of Haematology|October 20, 2022
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemiaEvan J Barnes, Christopher A Eide, Andy Kaempf, et al.
Cancer Cell|July 9, 2010
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-AblMark A Gregory, Tzu L Phang, Paolo Neviani, et al.
Blood Advances|January 25, 2022
Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemiaStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2013
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteinsMonika A Davare, Anna Saborowski, Christopher A Eide, et al.
Pageof 9